Navigation Links
Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011
Date:6/24/2011

t and indirect medical expenses.(iv)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(v) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(vi) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vii, viii)

About BYETTA® (exenatide) injection

BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not currently recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been studied in people who have pancreatitis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss (BYETTA is not a weight-loss product). BYETTA was approved in the U.S. in April 2005 and in Europe in November 2006 and has been used by more than 1.8 million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) inje
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
2. Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
3. PRA Early Phase Leaders to Speak at Bioanalysis Forum
4. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
5. Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries
6. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
7. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
8. Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation ... announced that it has received commitments from institutional ... million of the Company,s common stock in an ... health care fund. The Company entered ... to which the Company agreed to sell an ...
(Date:1/15/2014)... -- BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ... Ltd (NYSE: TEVA ) and its subsidiaries ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ... VSRNAs are of molecular size less than 10 bps, ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... RALEIGH, N.C., Feb. 17, 2011 BioDelivery Sciences International, ... enrollment of its Phase 3 trial assessing the efficacy ... moderate to severe chronic pain is on schedule, with ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) "We are very pleased ...
... Feb. 17, 2011 Reportlinker.com announces ... is available in its catalogue: ... - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
Cached Medicine Technology:BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 2BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 3Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Fla., July 31 Sky Development Inc.,announces that ... of the first of two Class A medical ... Center at 2201 North University Drive,Pembroke Pines, Florida ... The medical/professional office complex, with smart building technology,and ...
... may represent an increased risk of developing cardiovascular disease, ... academic journal Atherosclerosis , has now led to ... , Atherosclerosis (hardening of the arteries) is an inflammatory ... are thickened and become less elastic. It can cause ...
... 31 Affiliated Computer Services,Inc. (NYSE: ACS ... $100,million, with UMass Memorial Health Care, Inc., a ... The contract will extend an existing six-year business,relationship., ... will provide a cost-effective,method of expanding UMass Memorial,s ...
... with the Most Cost-Effective 2-3 Year,Plan for Achieving ... HATBORO, Pa., July 31 InfoLogix, Inc.,(Nasdaq: ... mobility and,advanced wireless asset tracking solutions for the ... launched a new Strategic,Mobility Assessment Service for hospitals ...
... Miami Herald providing online readers with a fully-branded implementation of ... ... Miami, FL (PRWEB) July 31, 2008 -- HealthCare.com, Inc. ... today announced a partnership whereby The Miami Herald Media Company, ...
... Nutraceutical,International Corporation (Nasdaq: NUTR ) today reported results ... Net sales for the fiscal,2008 third quarter were $40.5 ... fiscal 2007. For the third quarter of fiscal 2008, ... share, compared to,net income of $2.9 million, or $0.25 ...
Cached Medicine News:Health News:50% Pre-Leased at Park Plaza Professional Center in Pembroke Pines 2Health News:New discovery may lead to immunization against cardiovascular disease 2Health News:ACS Signs Five-Year, $100 Million Deal to Provide Technology Services to UMass Memorial Health Care, Inc. 2Health News:ACS Signs Five-Year, $100 Million Deal to Provide Technology Services to UMass Memorial Health Care, Inc. 3Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 2Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 3Health News:HealthCare.com Adds The Miami Herald to its Care Provider Search™ Network 2Health News:HealthCare.com Adds The Miami Herald to its Care Provider Search™ Network 3Health News:Nutraceutical Reports Q3 Results 2Health News:Nutraceutical Reports Q3 Results 3Health News:Nutraceutical Reports Q3 Results 4Health News:Nutraceutical Reports Q3 Results 5Health News:Nutraceutical Reports Q3 Results 6
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Four way compression with five contact closures...
Applies pressure on scalp to stretch it before surgery...
Facial Mask...
Medicine Products: